Sensorion Secures €60 Million Financing to Advance Hearing Loss Therapies

Sensorion has announced a significant €60 million financing package aimed at advancing its gene therapy programs. The initiative includes a strategic investment of €20 million from Sanofi, marking their entry as a key stakeholder. Existing investors such as Redmile Group, Artal, advised by Invus, and Sofinnova Partners are supporting the move, alongside U.S. funds like Cormorant Asset Management.

This funding extends Sensorion's financial runway until mid-2027. It will facilitate the approval and patient enrollment of SENS-601, a genetically targeted treatment for hearing loss due to GJB2 mutations, and continue the development of SENS-501, already progressing clinically.

The financing will be secured through the issuance of 214 million new shares at €0.28 each, set to enhance research endeavors significantly. Post-transaction, Sensorion's shares will continue trading on Euronext Paris.